

STREIS Statement – Checklist of items that should be included in reports of immunogenomic studies.

Item <sup>[1]</sup>	No. <sup>[1]</sup>	Strobe Guideline <sup>[1]</sup>	STREGA Guideline <sup>[1]</sup>	Extension for Immunogenomic Studies (STREIS)
<b>Methods</b>				
Variables	7	(a) Clearly define all outcomes, exposures, predictors, potential cofounders, and effect modifiers. Give diagnostic criteria, if applicable.	(b) Clearly define genetic exposures (genetic variants) using a widely-used nomenclature system. Identify variables likely to be associated with population stratification (confounding by ethnic origin)	(c) Describe HLA alleles in accordance with WHO Nomenclature Committee for Factors of the HLA System. Identify the IMGT/HLA Database release number pertinent to the data. (d) Describe KIR alleles in accordance with the IPD-KIR Database. Identify the IPD-KIR Database release number pertinent to the data.
Data sources/ measurement	8	(a) For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group.	(b) Describe laboratory methods, including source and storage of DNA, genotyping methods and platforms (including the allele calling algorithm used, and its version), error rates and call rates. State the laboratory/center where genotyping was done. Describe comparability of laboratory methods if there is more than one group. Specify whether genotypes were assigned using all of the data from the study simultaneously or in smaller batches.	(c) Provide access to the primary, ambiguous genotype data for each subject. (d) Describe the system(s) used to store, manage, and validate genotype and allele data, and to prepare data for analysis. (e) Use objective terms, identifying the assessed features of each gene, to describe genotyping systems and genotyping results. Avoid using subjective terms (e.g. low-, intermediate-, high-, or allele-resolution), that that may change over time, to describe genotyping systems and results. (f) Document all methods applied to resolve ambiguity. (g) Define any codes used to represent ambiguities. (h) Describe any binning or combining of alleles into common categories that was performed.
Statistical Methods	12	(a) Describe all statistical methods, including those used to control for confounding.	State software version used and options (or settings) chosen.	(b) Discuss any modifications made to the data in order to have them comport to the expectations of a method for the purpose of analysis. (c) Document any caveats associated with each analysis as they pertain to immunogenomic data.
<b>Discussion</b>				
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias.		(a) Discuss the impact of any modifications made to the data for the purpose of analysis. (b) Discuss any caveats associated with each analysis as they pertain to immunogenomic data. (c) Discuss any potential impact of ambiguity resolution on the results.

These STREIS checklist items are extensions of four items included on the STREGA checklist<sup>[1]</sup>. The article by Hollenbach et al.<sup>[2]</sup> provides background and context for each STREIS checklist item. Additional checklist items included under the STROBE<sup>[3]</sup> and STREGA guidelines should be considered for reports of immunogenomic studies.

1. Little, J., et al., *STrengthening the REporting of Genetic Association Studies (STREGA)--an extension of the STROBE statement*. Genet Epidemiol, 2009. **33**(7): p. 581-98.
2. Hollenbach, J.A., et al., *A community standard for immunogenomic data reporting and analysis: proposal for a STrengthening the REporting of Immunogenomic Studies statement*. Tissue Antigens, 2011. **78**(5): p. 333-44.
3. von Elm, E., et al., *The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies*. Epidemiology, 2007. **18**(6): p. 800-4.